D
Tarsus Pharmaceuticals, Inc.
TARS
$46.47
$2.906.66%
D
Sell
7/24/2023Upgraded
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D- from E+ on 7/24/2023 due to an increase in the total return index and volatility index.
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D- from E+ on 7/24/2023 due to an increase in the total return index and volatility index.
E
Sell
7/7/2023Downgrade
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E+ from D- on 7/7/2023 due to a decline in the volatility index.
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E+ from D- on 7/7/2023 due to a decline in the volatility index.
D
Sell
6/21/2023Upgraded
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D- from E+ on 6/21/2023 due to an increase in the total return index and volatility index.
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D- from E+ on 6/21/2023 due to an increase in the total return index and volatility index.
E
Sell
6/5/2023Downgrade
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E+ from D- on 6/5/2023 due to a decline in the volatility index.
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E+ from D- on 6/5/2023 due to a decline in the volatility index.
D
Sell
5/18/2023Upgraded
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D- from E+ on 5/18/2023 due to a noticeable increase in the growth index and volatility index.
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D- from E+ on 5/18/2023 due to a noticeable increase in the growth index and volatility index.
E
Sell
5/9/2023Downgrade
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E+ from D- on 5/9/2023 due to a decline in the volatility index.
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E+ from D- on 5/9/2023 due to a decline in the volatility index.
D
Sell
4/24/2023Upgraded
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D- from E+ on 4/24/2023 due to an increase in the volatility index.
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D- from E+ on 4/24/2023 due to an increase in the volatility index.
E
Sell
4/6/2023Downgrade
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E+ from D- on 4/6/2023 due to a decline in the total return index and volatility index.
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E+ from D- on 4/6/2023 due to a decline in the total return index and volatility index.
D
Sell
3/22/2023Upgraded
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D- from E+ on 3/22/2023 due to an increase in the volatility index and solvency index.
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D- from E+ on 3/22/2023 due to an increase in the volatility index and solvency index.
E
Sell
3/14/2023Downgrade
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index and total return index.
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index and total return index.
D
Sell
11/11/2022Downgrade
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to D- from D on 11/11/2022 due to a substantial decline in the growth index. EBIT declined 338.48% from -$5.22M to -$22.91M, operating cash flow declined 336.98% from -$4.26M to -$18.61M, and earnings per share declined from -$0.24 to -$0.8443.
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to D- from D on 11/11/2022 due to a substantial decline in the growth index. EBIT declined 338.48% from -$5.22M to -$22.91M, operating cash flow declined 336.98% from -$4.26M to -$18.61M, and earnings per share declined from -$0.24 to -$0.8443.
D
Sell
5/16/2022Upgraded
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E+ from D on 5/13/2022 due to a noticeable decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.7219 to -$0.98, EBIT declined 35.11% from -$14.45M to -$19.52M, and operating cash flow declined 26.11% from -$12.12M to -$15.29M.
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E+ from D on 5/13/2022 due to a noticeable decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.7219 to -$0.98, EBIT declined 35.11% from -$14.45M to -$19.52M, and operating cash flow declined 26.11% from -$12.12M to -$15.29M.
D
Sell
5/4/2022Upgraded
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D from E+ on 5/4/2022 due to an increase in the valuation index.
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D from E+ on 5/4/2022 due to an increase in the valuation index.
E
Sell
5/1/2022Downgrade
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index and total return index.
D
Sell
4/21/2022Upgraded
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E+ from D on 4/20/2022 due to a noticeable decline in the total return index and volatility index.
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E+ from D on 4/20/2022 due to a noticeable decline in the total return index and volatility index.
D
Sell
1/12/2022Upgraded
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D from D- on 1/12/2022 due to a noticeable increase in the total return index, volatility index and valuation index.
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D from D- on 1/12/2022 due to a noticeable increase in the total return index, volatility index and valuation index.
D
Sell
12/16/2021Downgrade
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to D- from D on 12/16/2021 due to a noticeable decline in the total return index, growth index and solvency index. Earnings per share declined from $0.2869 to -$0.7605, EBIT declined 315.67% from $7.28M to -$15.71M, and total revenue declined 94.37% from $22.02M to $1.24M.
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to D- from D on 12/16/2021 due to a noticeable decline in the total return index, growth index and solvency index. Earnings per share declined from $0.2869 to -$0.7605, EBIT declined 315.67% from $7.28M to -$15.71M, and total revenue declined 94.37% from $22.02M to $1.24M.
D
Sell
11/3/2021Upgraded
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D from D- on 11/3/2021 due to a major increase in the solvency index, growth index and total return index. Operating cash flow increased 274.25% from -$11.79M to $20.55M, and the quick ratio increased from 18.64 to 18.83.
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D from D- on 11/3/2021 due to a major increase in the solvency index, growth index and total return index. Operating cash flow increased 274.25% from -$11.79M to $20.55M, and the quick ratio increased from 18.64 to 18.83.
D
Sell
7/1/2021Upgraded
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D- from E+ on 7/1/2021 due to a substantial increase in the solvency index.
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to D- from E+ on 7/1/2021 due to a substantial increase in the solvency index.
E
Sell
4/1/2021Upgraded
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to E+ from E on 4/1/2021 due to a large increase in the total return index and valuation index.
Tarsus Pharmaceuticals, Inc. (TARS) was upgraded to E+ from E on 4/1/2021 due to a large increase in the total return index and valuation index.
E
Sell
1/12/2021None
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E from U on 01/12/2021.
Tarsus Pharmaceuticals, Inc. (TARS) was downgraded to E from U on 01/12/2021.
NASDAQ
03/07/2025 4:00PM Eastern
Quotes delayed
